John Geisler

Company: Mitochon Pharmaceuticals

Job title: Chief Scientific Officer

Seminars:

ALS, Secondary Progressive MS & Alzheimer’s Disease: Commonly Rooted in Mitochondrial Dysfunction in a 14-Day MP-101 Clinical CSF Biomarker Basket Study 11:00 am

MP-101: Lowers damage while promoting repair MP-101: Mitochondrial-specific, biophysics MOA, non-genomic pharmacology cascading into cellular remodeling MP-101: Oral brain penetrating once-per-day treatment waking up compensatory mechanism Pro-SurvivalRead more

day: CONFERENCE DAY ONE